Takeda Pharmaceutical and its partner CSL Behring have teamed up with plasma companies Biotest, BPL, LFB and Octapharma to develop a hyperimmune therapy for Covid-19.
The partners aim to immediately create an unbranded, plasma-derived polyclonal hyperimmune immunoglobulin therapy to treat serious complications associated with the novel coronavirus infection.
As part of the collaboration, the companies will leverage their expertise and ongoing work. Partnerships of experts under the alliance will form for plasma collections, clinical trial development and manufacturing activities.
Takeda hyperimmune therapy requires plasma donation from several people who recovered from Covid-19 and have coronavirus antibodies in their blood.